Inhibition of constitutive activity of the atypical chemokine receptor 3 by the small-molecule inverse agonist VUF16840
Mol Pharmacol. 2025 Oct 26;107(12):100085. doi: 10.1016/j.molpha.2025.100085. Online ahead of print.ABSTRACTThe atypical chemokine receptor 3 (ACKR3) has emerged as a promising drug target for the treatment of cancer, cardiovascular, and autoimmune diseases. In this study, we present the pharmacolog

